CClinicalTrials.gg
CompletedNCT03208699EXPALIUpdated Jul 6, 2017

EXPert System, ALImentary

An observational study in Eating Disorder Symptom, sponsored by Marie-Pierre TAVOLACCI. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-06.

Sponsored by Marie-Pierre TAVOLACCI · Observational

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
256
Ages
18 Years and older
Sex
All
01

Study summary

Eating disorders (ED) are often undetected in the general population resulting in delayed treatment. The SCOFF questionnaire has been validated for eating disorders screening in primary care, but does not identify the type of eating disorder.

Objective: Investigators evaluated the performance of a clinical algorithm (ExpaliTM) combining answers to SCOFF questionnaire with Body Mass Index (BMI) to identify four Broad Categories of ED derived from DSM-5.

Design: Clinical algorithm (ExpaliTM) was developped from 104 combinations of BMI levels and answers to five SCOFF questions. Two senior ED specialists allocated each combination to one of the four Broad Categories of ED (DSM-5 diagnostics): restrictive disorder (anorexia nervosa typical, atypical and restrictive food intake disorders), bulimic disorder (typical and with low frequency or duration), hyperphagic disorder (binge eating disorders typical and with low frequency or duration) and other specified ED. The performance of ExpaliTM was evaluated on data from patients referred to the Nutrition Department including a precise DSM-5 diagnosis of ED, a positive SCOFF test (at least 2 "yes" answers) and BMI. Sensitivity, specificity values with a 95% confidence interval (95% CI) and Youden index were calculated for each category.

02

Conditions studied

  • Eating Disorder Symptom

Keywords

  • anorexia
  • bulimia
03

In context

Feeding and Eating Disorders

740 studies on the registry are indexed under Feeding and Eating Disorders; 159 are open to participants now.

This study's enrollment of 256 is above the median of 100 across 183 observational studies indexed under Feeding and Eating Disorders.

Browse Feeding and Eating Disorders studies →

Lead sponsor

Marie-Pierre TAVOLACCI is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients recruited in the Nutrition Department of Rouen University Hospital (France) for suspicion of Eating disorders

Inclusion criteria

  • eating disorders
  • SCOFF test = 2 or more

Exclusion criteria

Exclusion Criteria:

  • no eating disorders
  • SCOFF test = 0 or 1
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
256 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Sensivity and specificity of the clinical algorithm

    Time frame: inclusion

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03208699
Lead sponsor
Marie-Pierre TAVOLACCI
Responsible party
Marie-Pierre TAVOLACCI (Docteur, University Hospital, Rouen) — Sponsor-investigator
First posted
Jul 5, 2017
Start date
Oct 1, 2015
Primary completion
Oct 1, 2015
Completion
Dec 31, 2015
Last update
Jul 6, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion